Clinical trials: Delivery Systems
Parkinson's Disease
Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease
Safety study of AADC gene transfer (VY-AADC01) in subjects with Parkinson's disease.
- Trial name
- AADC (NCT01973543)
- Testing
- VY-AADC01
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Neurocrine Biosciences
Diabetes, Healthcare Professionals
Preference Study Between NovoFine® Autocover™ and a NovoFine® 8 mm Needle
This trial is conducted in Europe. The aim of this clinical trial is to assess the preference of 2 different needles used by nurses and health assistants.
- Conditions
- Diabetes, Healthcare Professionals, Delivery Systems
- Trial name
- NCT01024218
- Testing
- NovoFine® needle 8 mm, autocover needle
- Where
- Denmark
- Volunteers
- 78 people
- Sponsor
- Novo Nordisk A/S
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and…
- Trial name
- IMPULSE-EVO (NCT07444320)
- Testing
- FARAPULSE™ Pulsed Field Ablation (PFA) System
- Where
- 4 sites in Croatia, Czechia and 2 more
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Stroke
Evaluation of Transfer Kinematics and Kinetics in Patients Chronic Post-stroke Using the Tibion Bionic Leg
The objective of this clinical study is to examine the acute kinematics and kinetics of utilizing the Tibion Bionic Leg in a sample of chronic post-stroke patients performing sit-to-stand and stand-to-sit transfers across a range…
- Trial name
- NCT01626417
- Testing
- Tibion Bionic Leg
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Tibion Bionics, Inc.
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
- Conditions
- Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
- Trial name
- NCT06016088
- Testing
- RSP-1502, Tobramycin inhalation solution
- Where
- 22 sites in United States, Australia
- Volunteers
- 71 people
- Sponsor
- Respirion Pharmaceuticals Pty Ltd
Asthma
Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma
The purpose of this study was to assess the pharmacokinetics (PK) of fevipiprant (QAW039) delivered as a chewable tablet (CT) in pediatric asthma subjects aged 6 to < 12 years with asthma.
- Trial name
- NCT03650400
- Testing
- Fevipiprant
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Apnea, Bradycardia
microEEG for Neonatal Apnea, Bradycardia and Desaturation
The study utilizes microEEG (a novel miniaturized, FDA approved EEG device) to prospectively investigate the cerebral electrical activity of infants with Apnea, Bradycardia and Desaturation events.
- Conditions
- Apnea, Bradycardia, Premature Birth, Seizures
- Trial name
- NCT02436616
- Testing
- microEEG
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bio-Signal Group Corp.
Diabetic Foot Ulcer
Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers
The purpose of this study is to investigate the safety and effectiveness of a nitric oxide releasing solution, delivered as a footbath, to act as an antimicrobial treatment for participants presenting with a diabetic foot ulcer.
- Trial name
- NCT04755647
- Testing
- Nitric Oxide-Releasing Solution, Saline solution, hypotonic
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Sanotize Research and Development corp.
Smoking, Tobacco
A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an Electronic Nicotine Delivery System
This is a multi-site, open-label, single arm study to evaluate the rate of smoking abstinence by the end of the study with healthy adult consumers of cigarettes when provided with an e-cigarette over a 13 week study period.
- Trial name
- NCT07879638
- Testing
- FT25614, FT25615, FT25616
- Where
- 5 sites in United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Symptomatic Aortic Stenosis
Portico TAVI Implant With Transfemoral Delivery System
The purpose of this study is to assess the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and the SJM TAVI Transfemoral Transcatheter delivery system in subjects with severe symptomatic aortic stenosis (AS).
- Trial name
- NCT01493284
- Testing
- Transcatheter Aortic Valve Implantation
- Where
- 14 sites in Australia, Denmark and 3 more
- Volunteers
- 222 people
- Sponsor
- Abbott Medical Devices
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis
This is a single center, randomized, double-blind, cross-over trial (with a follow-on single-blind safety evaluation stage), assessing a ready-to-drink nutritional supplement used without PERT ("PERT-free"), nutritional…
- Trial name
- NCT04966897
- Testing
- Standard Nutritional Supplement + PERT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlycosBio, Inc.
Sensory Perceptual Characteristics, User Acceptability of Gel Delivery System
Perception & Acceptability of a Cervical Cancer Prevention Prebiotic Device
PreBioGyn will be compared to market leading vaginal pH buffering gels using established forearm test methods associated with vaginal lubricity sensation in 42 women.
- Trial name
- NCT04841629
- Testing
- PreBioGyn Gel, Trimosan Gel, RepHresh Gel
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Glyciome, LLC
Asthma
Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.
This is an open-label, two part, six period- cross over, randomised, single dose, single centre study in healthy subjects. This is the first clinical study for the UD-DPI. This study is divided into two parts.
- Trial name
- NCT01984086
- Testing
- Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinitis
MP-AzeFlu Allergen Chamber - Onset of Action Study
This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an…
- Trial name
- NCT03004131
- Testing
- Azelastine hydrochloride + fluticasone propionate nasal spray, fluticasone propionate nasal spray + loratadine
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Dravet Syndrome
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
WAYFINDER is a Phase 1/2 study in Australia to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to <84 months. The study follows an open-label, dose-escalation design.
- Trial name
- NCT06112275
- Testing
- ETX101
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- Encoded Therapeutics
Rheumatoid Arthritis
Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis
This is an open-label pilot study in patients with rheumatoid arthritis (RA). All patients will receive SOFUSA Enbrel 25 mg once weekly.
- Trial name
- NCT04559412
- Testing
- Sofusa DoseConnect, Enbrel
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sorrento Therapeutics, Inc.
Smoking, Tobacco
CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers
The purpose of this Actual Use Study (AUS) is to investigate how United States (US) adult tobacco consumers 21 to 60 years of age, inclusive, who are regular smokers (≥5 cigarettes/day on at least 20 of the past 30 days) will use…
- Trial name
- NCT05960305
- Testing
- P1213416, P1213422, P1213716
- Where
- 12 sites in United States
- Volunteers
- 1,845 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin
This trial is conducted in Europe. The aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00569998
- Testing
- NovoPen™ 4, NovoPen® 3
- Where
- 23 sites in Austria, Germany and 3 more
- Volunteers
- 208 people
- Sponsor
- Novo Nordisk A/S
Healthy
Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects
To investigate the repeated dose Pharmacokinetics (PK) of transdermally delivered Rotigotine in Japanese and Caucasian female and male healthy subjects.
- Trial name
- NCT01854216
- Testing
- Rotigotine transdermal patch 1mg / 24 hours, Rotigotine transdermal patch 2 mg / 24 hours, Rotigotine transdermal patch 4 mg / 24 hours
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- UCB BIOSCIENCES GmbH